Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report

Joint Bone Spine

Volumn 77, Issue 5, 2010, Pages 484-485

  Caramaschi, Paola ^a   Ravagnani, Viviana ^a   Bambara, Lisa Maria ^a   Biasi, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Drug induced lupus; Infliximab; Psoriasis

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANTIBODY TITER; CASE REPORT; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FEVER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOFLUORESCENCE TEST; LABORATORY TEST; LETTER; LUPUS LIKE SYNDROME; POLYARTHRITIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RISK FACTOR; SEROCONVERSION; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; DRUG TOXICITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957871126     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.033     Document Type: Letter

References (9)

1. Charles P.J., Smeenk R.J., De Jong J., et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
2. De Rycke L., Kruithof E., Van Damme N., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
3. Caramaschi P., Biasi D., Colombatti M., et al. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006, 26:209-214.
4. De Bandt M., Sibilia J., Le Loet X., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545-R551.
5. Ramos-Casals M., Brito-Zeron P., Munoz S., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
6. Brito-Zerón P., Soto M.J., Cuadrado M.J., et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
7. Ji J.D., Lee W.J., Kong K.A., et al. Association of STAT4 polymorphism with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 2010, 37(1):141-147.
8. Zervou M.I., Goulielmos G.N., Castro-Giner F., et al. STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol 2009, 70:738-741.
9. Lee Y.H., Rho Y.H., Choi S.J., et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases - a meta-analysis. Rheumatology (Oxford) 2007, 46:49-56.